Immunotherapy versus chemotherapy as adjuvant therapy for resected MSI-H/dMMR colorectal cancer: real-world evidence informing precision strategies
MSI-H/dMMR CRC exhibits excellent prognosis after radical surgery. Postoperative WW remains the preferred strategy for Stage II patients, While patients with stage III requires intensive adjuvant therapy, and immunotherapy may surpass conventional chemotherapy recommended by the current guidelines.
Authors
- Fuqi Wang (ORCID: https://orcid.org/0009-0007-1782-4769)
- Sifan Zhai
- Weitang Yuan
- Quanbo Zhou (ORCID: https://orcid.org/0000-0001-9554-063X)
- Mengfei Zhao
- Pin Lyu (ORCID: https://orcid.org/0000-0002-9996-826X)
- Haifeng Sun (ORCID: https://orcid.org/0000-0002-3496-8103)
- Shuaixi Yang (ORCID: https://orcid.org/0009-0000-7048-8492)
Institutions
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1664684
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Zhengzhou University